HK1247123A1 - 治疗copd和其它炎症性病况的组合物和方法 - Google Patents

治疗copd和其它炎症性病况的组合物和方法 Download PDF

Info

Publication number
HK1247123A1
HK1247123A1 HK18106856.0A HK18106856A HK1247123A1 HK 1247123 A1 HK1247123 A1 HK 1247123A1 HK 18106856 A HK18106856 A HK 18106856A HK 1247123 A1 HK1247123 A1 HK 1247123A1
Authority
HK
Hong Kong
Prior art keywords
active agent
pde4b
pde4b2
expression
pka
Prior art date
Application number
HK18106856.0A
Other languages
English (en)
Chinese (zh)
Inventor
Li Jian-Dong
Original Assignee
生活燃料有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生活燃料有限公司 filed Critical 生活燃料有限公司
Publication of HK1247123A1 publication Critical patent/HK1247123A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18106856.0A 2015-03-20 2016-03-21 治疗copd和其它炎症性病况的组合物和方法 HK1247123A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136115P 2015-03-20 2015-03-20
US62/136,115 2015-03-20
PCT/US2016/023475 WO2016154143A1 (en) 2015-03-20 2016-03-21 Compositions and methods for treating copd and other inflammatory conditions

Publications (1)

Publication Number Publication Date
HK1247123A1 true HK1247123A1 (zh) 2018-09-21

Family

ID=56979181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106856.0A HK1247123A1 (zh) 2015-03-20 2016-03-21 治疗copd和其它炎症性病况的组合物和方法

Country Status (6)

Country Link
US (1) US11045456B2 (enExample)
EP (1) EP3270921A4 (enExample)
JP (1) JP6960855B2 (enExample)
CN (1) CN107427500A (enExample)
HK (1) HK1247123A1 (enExample)
WO (1) WO2016154143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500861A (ja) * 2017-09-27 2021-01-14 ユニバーシティ オブ サザン カリフォルニア 共刺激のための新規のプラットフォーム、新規のｃａｒ設計、および養子細胞療法のための他の増強

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
US20100316631A1 (en) * 2006-10-19 2010-12-16 The Uab Research Foundation Water Soluble Curcumin-Based Compounds
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
AU2009321723A1 (en) * 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of HIF-1 protein accumulation
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
US9951335B2 (en) * 2012-04-10 2018-04-24 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD

Also Published As

Publication number Publication date
CN107427500A (zh) 2017-12-01
WO2016154143A1 (en) 2016-09-29
JP2018510153A (ja) 2018-04-12
US20180042904A1 (en) 2018-02-15
US11045456B2 (en) 2021-06-29
EP3270921A1 (en) 2018-01-24
JP6960855B2 (ja) 2021-11-05
WO2016154143A8 (en) 2017-09-28
EP3270921A4 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
Chen et al. Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
US20230092181A1 (en) Intermittent dosing of mdm2 inhibitor
Kumar et al. 2-Deoxyglucose drives plasticity via an adaptive ER stress-ATF4 pathway and elicits stroke recovery and Alzheimer’s resilience
CN113631563A (zh) 用于治疗、预防或逆转年龄相关炎症和疾病的组合物和方法
WO2009045397A1 (en) Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases
JP2022078996A (ja) 重篤なインフルエンザの治療又は予防のための方法及び化合物
US20120294956A1 (en) Inhibition of dynamin related protein 1 to promote cell death
Lawrence et al. E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity
BRPI0721697A2 (pt) " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
Li et al. Exendin-4 promotes endothelial barrier enhancement via PKA-and Epac1-dependent Rac1 activation
Connolly et al. Caffeine modulates CREB-dependent gene expression in developing cortical neurons
JP2021535152A (ja) 神経変性障害を処置するためのｒｉｐキナーゼの阻害法
JP2020537122A (ja) 老化細胞のためのバイオマーカー
JP2025081323A (ja) ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US9951335B2 (en) Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD
US10189795B2 (en) Aryl amine substituted quinoxaline used as anticancer drugs
CN1980681A (zh) GSK－3β的调节及治疗增殖性病变的方法
US9963701B2 (en) Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
CN107921028A (zh) 治疗葡萄膜黑素瘤的mdm2抑制剂
US11045456B2 (en) Compositions and methods for treating COPD and other inflammatory conditions
WO2017143070A1 (en) Combination therapy
CN114432302A (zh) 小分子sr9009在抗衰老以及减轻衰老引起的慢性炎症中的用途
Lei et al. PARP (Poly ADP‐ribose Polymerase) Family in Health and Disease
Gu et al. Unlocking the potential of atractylenolide II: mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay